...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?
【24h】

Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?

机译:每天有10008例兰索拉唑使用者腹泻的特征:哪些辅助因素起作用?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Diarrhoea is one of the most frequently reported adverse events during proton pump inhibitor use in any setting. Because of the limited available information, this study was set up with the aim of assessing the incidence and characteristics of diarrhoea and to investigate possible associated co-factors in proton pump inhibitor users in daily practice. METHODS: Data were used from a prospective, observational study in which 10,008 lansprazole users were followed over time (1994-1998). The study was designed according to the SAMM guidelines. A nested case-control design was used to compare proton pump inhibitor users reporting diarrhoea with those reporting no diarrhoea. RESULTS: The frequency of diarrhoea was 3.7% and the incidence density 10.7 per 1000 patients months of proton pump inhibitor use. The diarrhoea was most commonly loose and occurred on average 4.4 times per day. The analysis of co-factors revealed that patients with concomitant use of oral antibiotics and patients reporting neurological and/or dermatological adverse events, were at risk of developing diarrhoea during proton pomp inhibitor use. CONCLUSIONS: In conclusion, diarrhoea was as frequently reported in our study as in clinical trials and observational data of lansoprazole users. We found the concomitant use of oral antibiotics and the reporting of certain other adverse events to be associated with the reporting of diarrhoea during lansoprazole use. Although a relationship with the proton pump inhibitor intake seemed very plausible, we recommend that use of concomitant medicines as a cause of diarrhoea must be taken into consideration in lansoprazole users.
机译:目的:腹泻是在任何情况下使用质子泵抑制剂期间最常报告的不良事件之一。由于可用信息有限,因此本研究旨在评估腹泻的发生率和特征,并在日常实践中调查质子泵抑制剂使用者中可能的辅助因素。方法:采用前瞻性观察性研究的数据,该研究随时间推移(1994-1998年)随访了10,008名兰斯拉唑使用者。该研究是根据SAMM指南设计的。巢式病例对照设计用于比较报告腹泻的质子泵抑制剂使用者和未报告腹泻的质子泵抑制剂使用者。结果:腹泻的发生率为3.7%,每使用1000名患者使用质子泵抑制剂月的发生密度为10.7。腹泻最常见,每天平均发生4.4次。对辅助因素的分析显示,同时使用口服抗生素的患者以及报告神经系统和/或皮肤病学不良事件的患者在使用质子盛放抑制剂时有腹泻的风险。结论:总的来说,腹泻是兰索拉唑使用者在临床研究和观察数据中经常报道的现象。我们发现,同时使用口服抗生素和某些其他不良事件的报告与使用兰索拉唑期间腹泻的报告有关。尽管与质子泵抑制剂摄入的关系似乎很合理,但我们建议兰索拉唑使用者必须考虑使用引起腹泻的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号